F.D.A. Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works

Aducanumab, or Aduhelm, is the first new Alzheimer’s treatment in 18 years and the first to attack the disease process. But some prominent experts say there’s not enough evidence it can address cognitive symptoms.

Share:

Facebook
Twitter
Pinterest
LinkedIn

Leave a Reply

Related Posts

Regulations of crypto

Cryptocurrency Regulations Worldwide

How Countries Are Shaping the Future of Digital Currencies Cryptocurrencies have revolutionized the global financial landscape, offering decentralized alternatives to traditional banking systems. But as